Summit Therapeutics (SMMT) Other financing activities (2020 - 2026)

Summit Therapeutics' Other financing activities history runs 7 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• Quarterly Other financing activities fell 32.89% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 99.14% YoY) and the FY2025 annual result came in at $5.7 million, down 98.7% from the prior year.
• Other financing activities was $3.8 million for Q1 2026 at Summit Therapeutics, up from -$1.7 million in the prior quarter.
• Across five years, Other financing activities topped out at $432.6 million in Q4 2024 and bottomed at -$197.8 million in Q3 2024.
• A 5-year average of $31.8 million and a median of $419000.0 in 2022 frame the typical range for Other financing activities.
• Peak annual rise in Other financing activities reached 46468.35% in 2024, while the deepest fall reached 30277.88% in 2024.
• Summit Therapeutics' Other financing activities stood at $104000.0 in 2022, then soared by 793.27% to $929000.0 in 2023, then jumped by 46468.35% to $432.6 million in 2024, then slumped by 100.38% to -$1.7 million in 2025, then jumped by 328.46% to $3.8 million in 2026.
• Business Quant data shows SMMT's Other financing activities at $3.8 million in Q1 2026, -$1.7 million in Q4 2025, and $7.3 million in Q3 2025.